Children in the study were admitted to the pediatric department of one hospital between January 2020 and February 2024. Researchers randomly divided the cohort into a training set of 255 patients and a validation set of 109, producing a 7:3 split. The inputs comprised 20 indicators drawn from demographic information, clinical test results, imaging features and text contained in electronic medical records. Baseline characteristics did not differ significantly between the two subsets, according to the reported analysis with P values greater than 0.05.

The analysis proceeded in stages. Candidate predictors were first screened through univariate analysis, after which feature dimension was reduced with least absolute shrinkage and selection operator, or LASSO, regression. Multivariable logistic regression then identified factors independently associated with respiratory failure occurring alongside severe pneumonia. Seven variables met the study’s threshold of P less than 0.05: fraction of inspired oxygen, C-reactive protein, serum lactate, the number of affected lung lobes, entropy of the gray-level co-occurrence matrix, contrast of the gray-level run-length matrix, and the absolute value of first-order statistical skewness. The first three were clinical measurements, while the final four were CT-derived variables.

Based on the combined data, the researchers constructed Random Forest, Support Vector Machine and Gradient Boosting Machine prediction models. Their performance was evaluated with the area under the receiver operating characteristic curve, sensitivity and specificity. In the training set, Random Forest produced the highest AUC at 0.893, with a 95% confidence interval of 0.826–0.961. The corresponding AUC was 0.836 for Support Vector Machine, with a 95% confidence interval of 0.756–0.916, and 0.854 for Gradient Boosting Machine, with a 95% confidence interval of 0.783–0.924. Random Forest also maintained the best discriminative performance in the validation set, although the supplied abstract does not provide the numerical AUC, sensitivity or specificity for that subset. DeLong tests found a statistically significant difference between Random Forest and Support Vector Machine at P = 0.018, and between Random Forest and Gradient Boosting Machine at P = 0.042.

The analysis highlighted the contrast of the gray-level run-length matrix, entropy of the gray-level co-occurrence matrix, the absolute value of first-order statistical skewness and the number of affected lung lobes as core early-warning factors. Together with fraction of inspired oxygen, C-reactive protein and serum lactate, these variables formed a compact set of laboratory, oxygenation and imaging predictors identified in the multivariable analysis. The reported results show that fusing CT and electronic medical-record information yielded useful discrimination within this retrospective cohort, but important limitations constrain broader interpretation. The study included children already hospitalized at a single institution, used a validation set of 109 patients, and did not report external validation, calibration, decision thresholds or missing-data handling in the supplied abstract. It also assessed prediction of concurrent respiratory failure rather than whether acting on the model would enable earlier intervention. The article supplied for this report is an early, editable version subject to replacement by the final Version of Record.

Subject of Research: Retrospective prediction of concurrent respiratory failure in children hospitalized with severe pneumonia using combined CT and electronic medical-record data

Article Title: Prediction of respiratory failure in severe pediatric pneumonia via CT and electronic medical records fusion

Article References: Huang, C., & Zhang, N. (2026). Prediction of respiratory failure in severe pediatric pneumonia via CT and electronic medical records fusion. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07599-4

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07599-4

Keywords: pediatric pneumonia, respiratory failure, chest CT, electronic medical records, machine learning, Random Forest, risk prediction, medical imaging, retrospective study, Prediction, respiratory, failure

The study shows why a model can retain some ability to rank cases without assigning reliable probabilities, and why recalibrating those probabilities does not by itself repair weak external discrimination. This was a cross-dataset external-validation study, not a prospective clinical evaluation. The models were trained for five epochs with AdamW, a learning rate of 3 × 10−4, batches of 32 and class-imbalance-weighted binary cross-entropy.

The experiment was repeated across five random seeds, and the checkpoint with the lowest APTOS validation loss was retained for each. APTOS 2019 contained 3,662 labeled images, while Messidor-2 provided 1,744 gradable images. Of the target images, 523 formed a calibration pool and 1,221 were reserved for final testing.

All images were resized to 224 × 224 pixels and normalized with ImageNet statistics. The endpoint combined grade 0 with all higher grades as “any retinopathy,” rather than using the clinically common threshold for referable diabetic retinopathy, so the findings are methodological rather than estimates of screening performance. Before interpreting the strong internal result, investigators audited the APTOS splits for repeated images.

Exact matching of decoded RGB arrays identified 48 cross-split groups containing 97 images. A perceptual-hash screen followed by manual review added five non-exact pairs judged to be the same or a near-identical retinal capture. Altogether, 51 connected groups contained 105 images distributed across training, validation and test sets.

Eleven groups had discordant original grades, including one with a different binary label. Removing all 27 affected test images left 523 source test images and did not materially change the result: uncalibrated AUC remained 0.997 ± 0.002 and accuracy was 0.983 ± 0.006. The audit therefore argues against the recognized overlap explaining the high internal score, but it could not establish patient-level independence because the available table contained no patient or eye identifiers.

Probability calibration asks a different question from discrimination: whether a predicted risk corresponds to the observed frequency of the outcome. On Messidor-2, the uncalibrated positive-class probabilities were poorly aligned with outcome frequencies, producing equal-width and equal-mass 15-bin expected calibration error, or ECE, values of 0.266 ± 0.077 and 0.262 ± 0.077. Applying a temperature fitted on APTOS validation data changed almost nothing.

Across paired comparisons on the same 1,221 target test images, source-domain temperature scaling reduced equal-mass ECE by 0.0010 and the Brier score by 0.0006. Although these tiny differences were statistically detectable because the same images were reused, their magnitude was negligible, and the high-confidence error rate at a 0.9 threshold did not change significantly. Calibrating on small labeled samples from the target dataset was more effective.

In repeated sampling, researchers drew 200 random subsets at each of four sizes—25, 50, 100 and 200 labeled Messidor-2 images—with every subset containing both classes. The procedure produced 16,000 successful fits across five model seeds, four sample sizes, 200 draws and four methods: temperature scaling, Platt scaling, beta calibration and isotonic regression. Every fitted calibrator was evaluated on the same disjoint target test set.

With temperature scaling, mean equal-mass ECE declined from 0.108 at 25 labels to 0.085 at 200, mean Brier score improved from 0.233 to 0.227, and mean negative log-likelihood fell from 0.667 to 0.646. A constant predictor based only on the positive prevalence in each calibration subset was used as a reference; temperature scaling achieved a positive mean Brier skill score of 0.080–0.084 across the sample sizes. The best method depended on how much target data were available.

At 25 labels, temperature scaling had the lowest mean Brier score, negative log-likelihood and equal-mass ECE among the four calibrated approaches, while the more flexible methods were less stable. At 200 labels, beta calibration performed best, with a mean Brier score of 0.221, equal-mass ECE of 0.061, negative log-likelihood of 0.634 and Brier skill score of 0.104 relative to the prevalence-only predictor. Its mean accuracy was 0.651, compared with 0.639 for temperature scaling, while mean AUC ranged from 0.659 to 0.665 across methods.

These comparisons describe this experiment rather than establishing a universal ranking. The flexible calibrators could alter ranking or create ties, unlike positive temperature scaling, which preserves the order of the original logits and therefore leaves AUC, accuracy and the 0.5 decision threshold mathematically unchanged. The threshold results showed why “high-confidence error” cannot be interpreted in isolation.

In the fixed 100-label temperature calibration, the high-confidence error rate at a 0.9 threshold fell from 0.220 to 0.001. Yet coverage at that threshold also fell from 0.667 to 0.005: rather than making confident predictions correct, recalibration compressed probabilities toward 0.5 until almost no test images were retained as high confidence. Across all five seeds and 6,105 seed–image predictions, the uncalibrated model covered 4,075 images at the 0.9 threshold and made 1,342 errors, corresponding to conditional error of 0.329 with a 95% confidence interval of 0.315–0.344.

The 100-label temperature model covered only 30 images and made five errors, but its conditional error of 0.167 had a wider interval of 0.056–0.347, and three of five seeds had no covered image. The observed reduction in high-confidence error therefore mainly reflected the collapse in high-confidence coverage, not the removal of classification mistakes. Risk–coverage curves supplied an additional check on what recalibration could accomplish.

The curves for raw predictions, source temperature scaling and all target temperature fits overlapped because multiplying logits by a positive temperature changes their magnitude but not their order. Mean selective error was 0.311 at 60 percent coverage and 0.334 at 80 percent coverage in every temperature condition. Calibration changed the numerical confidence scale but did not improve which cases were retained at a given coverage.

The optimization audit also revealed instability in the smallest target samples: 69 of 4,000 repeated temperature fits reached the expanded upper temperature boundary of 403.43, including 55 of the 25-label fits, whereas none did at 200 labels. These boundary solutions define confidence-compressing mappings, but their fitted temperatures should not be treated as precise finite estimates. The observed shift included a difference in positive-label prevalence: 48.7 percent in the APTOS test set, 39.0 percent in the Messidor-2 calibration pool and 42.8 percent in the Messidor-2 test set.

The datasets also came from different collection sources, making acquisition-related differences plausible, but the study lacked harmonized camera, demographic and patient-level metadata needed to separate prevalence effects from other forms of covariate shift. A scalar temperature has no intercept and is not a dedicated correction for label shift. The analysis was restricted to one model family, one dataset pair, one binary endpoint and four calibration methods, and it did not test prospective workflows, subgroup calibration, referral decisions or patient safety.

Its central result is that calibration, coverage, conditional error, discrimination and optimizer diagnostics should be reported together: limited target labels can improve probability estimates, but they do not turn a weakly transferring retinal classifier into a clinically ready system.

Subject of Research: External calibration and limited-label recalibration of retinal image classifiers under dataset shift

Article Title: Calibration failure and limited-label recalibration of retinal image classifiers under dataset shift

Article References: Rahat, S. R. U. I., Shaikh, M. H., Sorna, I. J., & Mahajan, M. (2026). Calibration failure and limited-label recalibration of retinal image classifiers under dataset shift. Discover Artificial Intelligence, 6(1), Article 1549. https://doi.org/10.1007/s44163-026-02520-5

Image Credits: AI Generated

DOI: 10.1007/s44163-026-02520-5

Keywords: retinal imaging, diabetic retinopathy, probability calibration, dataset shift, external validation, temperature scaling, beta calibration, EfficientNet-B0, confidence thresholds, risk–coverage analysis, Calibration, failure

The study included patients diagnosed with pediatric Hodgkin lymphoma at a tertiary referral center in Iran from 2014 through 2024. Eligible participants had baseline positron emission tomography/computed tomography staging and complete outcome data; three additional patients without baseline staging were excluded. The analysis covered demographic, clinical, histopathological, laboratory, treatment and outcome information extracted from medical records. Treatment failure was defined as relapse following complete remission or primary refractory disease. Associations with failure were examined using univariate analyses, rather than a multivariable predictive model.

The cohort included 54 males, or 65.1%, and 29 females, or 34.9%), and the mean age at diagnosis was 10.72 ± 3.86 years. Stage III disease was the predominant presentation, accounting for 66.3% of patients. Younger age at diagnosis was associated with relapse: relapsing patients had a mean age of 8.29 ± 3.73 years, compared with 11.22 ± 3.72 years among those who did not relapse (p = 0.015). Elevated erythrocyte sedimentation rate, defined as ESR above 50 mm/hr, was also associated with relapse, occurring in 42.9% of relapsing patients and 11.6% of patients without relapse (p = 0.010).

Fever and night sweats at diagnosis were associated with primary refractory disease. Fever was present in 45.5% of patients with refractory disease, compared with 8.3% of those without it (p = 0.005), while night sweats were present in 36.4% and 8.3%, respectively (p = 0.024). Histological subtype, whether classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma, disease stage and the first-line chemotherapy regimen were not significantly associated with treatment failure. Among patients who experienced failure, ESHAP was the most frequently used salvage regimen, while 14 patients, or 16.9% of the full cohort, received brentuximab vedotin or nivolumab.

The findings are limited by the retrospective design, small single-center population, exclusion of three patients without baseline PET/CT staging and use of univariate associations. The results therefore identify features associated with relapse or refractory disease in this cohort but do not establish independent predictors or demonstrate that the reported factors caused treatment failure. The authors called for larger prospective studies to assess whether these associations can support risk stratification and inform treatment strategies.

Subject of Research: Factors associated with relapse and primary refractory disease in a retrospective cohort of 83 children with Hodgkin lymphoma in Iran

Article Title: Treatment failure and associated factors in pediatric Hodgkin lymphoma: a decade of institutional experience from a middle-income country

Article References: Farokhmanesh, S., Ghanbari, P., Karimzadeh, A., Zekavat, O. R., Bordbar, M., Shahriari, M., Zareifar, S., & Mottaghipisheh, H. (2026). Treatment failure and associated factors in pediatric Hodgkin lymphoma: a decade of institutional experience from a middle-income country. BMC Cancer. https://doi.org/10.1186/s12885-026-17031-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17031-w

Keywords: pediatric Hodgkin lymphoma, treatment failure, relapse, primary refractory disease, retrospective cohort, Iran, prognostic factors, PET/CT staging, salvage therapy, Treatment, failure, associated

The trial, led by Asghar Marzban and SeyedehFatemeh Mousavi of Zanjan University of Medical Sciences, set out to answer a deceptively simple question: if you give nebulized epinephrine on a fixed schedule after extubation, can you prevent the baby from failing to breathe on their own? Epinephrine, the same adrenaline-derived compound that has saved countless infants from croup, constricts blood vessels in the airway mucosa and is thought to shrink the edema that narrows the passage. It is widely used in neonatal units exactly for this purpose, often as a rescue treatment when stridor appears. But as the authors note, the randomized evidence supporting its prophylactic use in newborns has been thin, and the practice has persisted largely on physiological plausibility and clinical habit rather than on firm trial data.

To settle the question, the investigators designed a randomized, double-blind, placebo-controlled trial at the level III neonatal intensive care unit of Ayatollah Mousavi Hospital in Zanjan, running from May to December 2025. They enrolled invasively ventilated neonates who met standardized readiness criteria for their first planned extubation after less than seven days of intubation, with written informed consent from a parent or legal guardian. Neonates with contraindications to epinephrine, major congenital or structural upper-airway abnormalities, inherited metabolic or neuromuscular disorders, critical conditions at the time of extubation, or recent epinephrine exposure were excluded. The narrow focus on short-term intubation was deliberate: the longer a tube sits in the airway, the more complex the edema and the harder it is to attribute failure to a single reversible cause.

The intervention itself was meticulously standardized. Participants were randomized to receive nebulized L-epinephrine at a dose of 0.5 milligrams per kilogram per dose, drawn from a 1:1000 solution and diluted with saline to a total volume of four milliliters, or a volume-matched saline placebo. The drug was delivered through a nebulizer over fifteen minutes at an oxygen flow of six liters per minute, every twelve hours for three days, with continuous cardiorespiratory monitoring throughout. The primary outcome was extubation failure, defined as the need for reintubation within seventy-two hours. The team also tracked reintubation within twenty-four hours, forty-eight hours, and seven days as secondary, time-windowed analyses, along with post-extubation respiratory distress and adverse effects such as tachycardia.

Ninety-seven neonates were randomized, fifty-one to the epinephrine arm and forty-six to placebo. When the data came in, the primary endpoint showed no difference between the groups. Seven of the fifty-one babies in the epinephrine arm, or 13.7 percent, needed reintubation within seventy-two hours, compared with seven of the forty-six babies, or 15.2 percent, in the placebo arm. The risk ratio was 0.90 with a 95 percent confidence interval of 0.34 to 2.38, and the absolute risk difference was minus 1.5 percent with a confidence interval spanning from minus 15.5 percent to plus 12.5 percent. The p value was 1.00. In plain terms, the scheduled epinephrine regimen did nothing to reduce the likelihood that a baby would fail extubation in the critical first three days.

The time-windowed secondary analyses told the same story. Failure rates were similar at twenty-four hours, forty-eight hours, and seven days, and, notably, no reintubations occurred at all between seventy-two hours and seven days in either arm. Post-extubation respiratory distress was numerically lower with epinephrine, 13.7 percent versus 21.7 percent, but the difference was not statistically significant, with a risk ratio of 0.63 and a confidence interval of 0.26 to 1.52 and a p value of 0.423. Adverse effects were infrequent and balanced between the arms, with tachycardia rates of 3.9 percent in the epinephrine group and 4.3 percent in the placebo group. The regimen, in other words, was not associated with excess short-term harm, but neither did it deliver the benefit that clinicians have long hoped for.

The authors are careful to frame their conclusions within the statistical limits of the study. The confidence intervals were wide and did not exclude clinically meaningful benefit or harm. With only fourteen reintubations across both arms, the trial was powered for a much larger effect than the roughly 14 to 15 percent failure rate actually observed. A risk ratio of 0.90 with a confidence interval reaching down to 0.34 means the data are compatible with anything from a modest reduction to a substantial one, and equally with a modest increase in risk. The low event rate, paradoxically a sign of good neonatal care, makes it statistically harder to detect a true benefit, and the authors explicitly state that a clinically meaningful effect cannot be excluded on the basis of this trial alone.

What does this mean for the neonatal units that have been reaching for the nebulizer after every extubation? The most direct implication is that scheduled nebulized epinephrine, initiated after extubation in neonates ventilated for less than one week, should not be assumed to prevent extubation failure. The trial does not rule out benefit in selected subgroups, such as babies with more severe airway edema or those with specific risk factors for obstruction, and it does not address rescue use of epinephrine once stridor has already appeared. But as a one-size-fits-all prophylactic regimen, the fixed twelve-hourly dosing schedule tested here did not move the needle on the outcome that matters most: keeping the tube out.

The study also highlights a broader truth about neonatal intensive care research. Extubation failure remains a major challenge in the field, and post-extubation upper-airway obstruction due to mucosal edema is a potentially reversible contributor, which is precisely why the epinephrine hypothesis has endured. But the trial demonstrates how easily a plausible mechanism can fail to translate into clinical benefit when tested rigorously. The regimen was safe, with no excess adverse events, which means the negative result is not a story about harm but about the limits of a widely used practice. For clinicians, the message is that the decision to use nebulized epinephrine after extubation should rest on individual clinical judgment rather than on the assumption that a fixed schedule will protect every baby.

For now, the trial stands as a rigorous test of a common practice, registered prospectively in the Iranian Registry of Clinical Trials and approved by the ethics committee of Zanjan University of Medical Sciences. It does not close the book on nebulized epinephrine in neonates, but it does raise the bar for the evidence required before the drug is deployed as routine prophylaxis. As the authors conclude, scheduled nebulized epinephrine initiated after extubation in neonates ventilated for less than one week did not reduce extubation failure compared with placebo, and given the low event rate and wide confidence intervals, a clinically meaningful effect cannot be excluded. In the high-stakes world of the neonatal intensive care unit, where every breath counts and every tube removal is a calculated gamble, that is a finding worth taking seriously.

Subject of Research: Neonatology

Article Title: Nebulized epinephrine to prevent extubation failure in neonates after short-term intubation: a randomized, double-blind, placebo-controlled trial

Article References: Marzban, A., Mousavi, S., Mokhtari, S., Jafari, N., Bagherivand, M., Habibi, S., Esmaeili, F., & Motiei Langroudi, S. M. (2026). Nebulized epinephrine to prevent extubation failure in neonates after short-term intubation: a randomized, double-blind, placebo-controlled trial. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07825-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07825-z

Keywords: neonatology, extubation failure, nebulized epinephrine, randomized controlled trial, mechanical ventilation, upper airway obstruction, BMC Pediatrics, Nebulized, epinephrine, prevent, extubation, failure

The review’s central organizing principle is the target product profile, a specification that defines the indication, patient population, route, target compartment, onset and duration of action, dosing frequency, co-medications, and acceptable shedding. This profile is not paperwork; it is the yardstick against which every downstream engineering decision is measured. A design optimized for transient luminal metabolism, for instance, may be entirely unsuitable when tissue penetration or systemic protein exposure is required. The authors translate the profile into quantitative acceptance criteria: viable dose at release and at shelf-life end, activity per viable cell, basal and induced output, response time, and performance in biologically relevant matrices. The most common failure mode at this stage, they warn, is using colony-forming units as the sole measure of potency, a shortcut that conceals whether the engineered function actually survives manufacturing and storage.

Chassis selection emerges as a decision that constrains nearly everything else. The strain chosen determines survival during administration, activity in the target compartment, payload burden, interactions with the resident microbiota and immune system, antimicrobial susceptibility, manufacturability, and prior human exposure. Established probiotic chassis such as Escherichia coli Nissle 1917 and Lactococcus lactis offer human-use experience and accessible production methods, but they can be difficult to engineer, may express weakly in vivo, and often persist inconsistently. Human-derived next-generation commensals may fit a particular nutrient or spatial niche more closely, yet they can impose anaerobic manufacturing requirements, limited genetic tools, and unresolved safety questions. The review insists that safety cannot be assigned at the genus or species level; strain-level whole-genome sequencing combined with orthogonal identification and phenotyping for virulence, toxigenicity, antimicrobial resistance, and translocation potential is the minimum standard for an engineered derivative.

Genetic circuits, the engineered arrangements of regulatory DNA and interacting gene products that control therapeutic output, receive equally rigorous treatment. The authors decompose every circuit into separable functions: input sensing, signal processing, therapeutic output, and release. Constitutive expression may be appropriate when the tolerated exposure window is wide or when local substrate availability governs activity. Conditional expression is justified only when spatial or temporal restriction genuinely improves the intended exposure profile, and proving this requires testing clinically relevant cue ranges, off-target conditions, basal leakage, and activation and reset kinetics in heterogeneous biological samples. Candidate inputs include oxygen, pH, inflammatory mediators, metabolites, quorum signals, temperature, and externally supplied inducers. Logic gates, feedback, quorum sensing, and synchronized lysis can coordinate expression, but their performance depends intimately on the chassis and physiological setting. Programming Bacteroides thetaiotaomicron in the murine gut, the review notes, required chassis-specific promoters, inducible systems, and memory modules, a reminder that modular designs do not portend portability across organisms.

Payload pharmacology and release architecture form the next critical layer. Engineered LBPs can transform host or dietary metabolites, consume toxic substrates, produce small molecules, or express enzymes, peptides, binding proteins, cytokines, and antimicrobials. For intestinal delivery, a luminal enzyme may act without epithelial uptake, whereas a peptide intended for systemic action requires transport across the epithelial barrier. Active secretion, programmed lysis, and surface display each carry different implications for accessibility, viable-cell number, and exposure to microbial inflammatory components. The review highlights synchronized lysis circuits that generate pulsatile cargo release while a surviving subpopulation reseeds successive cycles, and modified type III secretion platforms that deliver functional nanobodies from engineered E. coli in the murine gut. In every case, the authors stress that payload identity, bioactivity, released fraction, target-site exposure, and host response must be measured independently of organism fate, because inferring exposure from transcription or bulk culture titre is a documented failure mode.

Fitness burden and evolutionary stability present perhaps the most fundamental constraint on circuit complexity. Therapeutic expression imposes a metabolic cost, allowing non-producing cells to outgrow producers through plasmid loss or mutation in the payload and its regulation. The review calls for paired sequence and functional measurements, with sampling designed to detect minority escape variants, across the maximum plausible generation count from seed expansion through in-patient residence. Endpoint sequencing alone, the authors caution, misses these escape variants. Candidate mitigation strategies include chromosomal integration, lower-burden expression, balanced pathway flux, marker-free selection, and coupling product maintenance to fitness. In one bioprocess example, synthetic product addiction prolonged mevalonic-acid production across 95 generations by tying output to essential cellular functions. Multilayer biocontainment receives similarly quantitative treatment: auxotrophy, conditional replication, kill switches, synthetic nutrient dependence, and physical barriers can provide complementary safeguards, but each contribution must be assessed through its measured function, with escape frequency reported alongside a stated denominator and detection limit. Toxin-antitoxin systems such as hok/sok, the review emphasizes, favor plasmid-bearing cells but constitute plasmid maintenance, not organismal or genetic containment.

The clinical evidence assembled in the review tells a story of mechanistic success paired with translational frustration. On the regulatory side, two FDA-approved donor-derived microbiota products for recurrent Clostridioides difficile infection provide precedents for live microbial medicines: REBYOTA, approved in November 2022, achieved 8-week treatment success of 70.6 percent versus 57.5 percent for placebo in a pivotal study of 262 adults, while VOWST, approved in April 2023, reduced 8-week recurrence to 12.4 percent versus 39.8 percent among 182 participants. Both approvals, however, are specific to their unengineered products and confer no class-wide authorization on recombinant strains. Among defined non-engineered products, LACTIN-V containing Lactobacillus crispatus CTV-05 reduced bacterial vaginosis recurrence by week 12 from 45 percent with placebo to 30 percent in a randomized phase 2b trial of 228 participants, and the 15-strain consortium MTC01 showed 7 of 9 recipients recurrence-free at 8 weeks without treatment-related adverse events in a small safety-focused phase 1b study.

The recombinant candidates present a more sobering picture. An early phase 1 study administered IL-10-secreting, thymidine-dependent Lactococcus lactis to 10 patients with Crohn’s disease, establishing feasibility and recovery of the modified organism without any controlled efficacy estimate. SYNB1020, an engineered EcN strain that converts gut ammonia to arginine, showed dose-dependent exposure and pathway activity in healthy volunteers, yet development was discontinued in August 2019 after an interim analysis revealed that blood ammonia did not fall in patients with cirrhosis despite the strain being well tolerated and raising urinary nitrogen. SYNB1618, a chromosomally engineered EcN strain that consumes phenylalanine, produced dose-responsive pathway metabolites in 56 healthy adults and 14 adults with phenylketonuria, with the strain clearing within 4 days after dosing. Its successor SYNB1934 reduced labeled phenylalanine exposure by 43 percent and fasting phenylalanine by 40 percent in a phase 2 trial, yet the pivotal SYNPHENY-3 study was terminated in 2024 because interim data indicated its primary endpoint was unlikely to be met. AG019, an oral engineered Lactococcus lactis delivering human proinsulin and IL-10 for recent-onset type 1 diabetes, supported its primary safety objective across 42 analyzed participants, but metabolic and immune findings remained exploratory. SYNB1891, an intratumoral EcN strain producing a STING agonist, demonstrated target engagement and stable disease in four of 32 phase 1 participants, with five cytokine-release-syndrome events including one dose-limiting toxicity, before the program was terminated for business reasons.

Adjacent oncology platforms share engineering constraints with LBPs but sit outside the conventional mucosal category. Intravenous attenuated Salmonella VNP20009 produced documented tumor colonization in only 3 of 25 participants with no objective responses in a landmark phase 1 study, while murine tropism failed to translate to humans. Intratumoral Clostridium novyi-NT achieved germination or lysis in 10 of 24 participants and reduction of the injected tumor in 9 of 22 evaluable participants, but grade 4 sepsis occurred in two participants and gas gangrene in one. These studies provide early human safety evidence, with randomized efficacy still to be established. The FDA LBP guidance explicitly excludes oncolytic bacteria and microbial gene-therapy vectors, and the European Medicines Agency’s 2026 concept paper on microbiome-based medicinal products expressly excludes genetically modified organisms classified as advanced therapy medicinal products, leaving recombinant LBPs in a regulatory territory that requires early authority consultation.

The review’s conclusion is neither dismissive nor celebratory. Licensed donor-derived products establish a manufacturing and clinical precedent for their specific categories and indications, while recombinant therapeutic strains chiefly possess early human evidence on safety, organism fate, and pharmacodynamic activity. The termination of the pivotal SYNB1934 study illustrates the need to test mechanistic activity against a prespecified patient-relevant efficacy endpoint, because surrogate validity cannot be assumed. Measurements of active-payload exposure in the intended compartment, induction across relevant biological variation, and retention of function during manufacture and administration provide a basis for comparing preclinical designs, but larger or additional animal models are informative only when they resolve a defined translational uncertainty. The authors call for chemistry, manufacturing, and controls to be co-developed with the genetic construct rather than treated as a downstream step, for formulation changes to trigger comparability strategies with nonclinical or clinical bridging when residual uncertainty warrants it, and for clinical trials to assess target engagement and patient benefit separately. Informed consent must cover the product’s capacity for replication, evolution, and shedding, expected clearance, limitations of withdrawal, and available rescue measures, informed by incidents such as the 2019 FDA report of extended-spectrum beta-lactamase-producing E. coli transmission through investigational fecal microbiota transplantation to two immunocompromised adults, one of whom died. The path forward, the review suggests, runs through quantitative rigor at every decision point, from the first specification of viable dose to the final measurement of patient benefit.

Subject of Research: Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation

Article Title: Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation

Article References: Shen, S., Zhao, J., & Gao, H. (2026). Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation. Frontiers in Microbiology, 17, Article 2002085. https://doi.org/10.3389/fmicb.2026.2002085

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.2002085

Keywords: Engineered, live, biotherapeutic, products, design, decisions, failure, modes, clinical, translation, scientific research

The team, led by researchers from Bohai University, Foshan University, Shenzhen Polytechnic University, and Zhejiang University, focused on particle-reinforced metal matrix composites, or PRMMCs, in which silicon carbide particles strengthen a 6061 aluminum matrix. These materials are prized because the hard ceramic carries load while the ductile metal absorbs energy, but their mechanical response has always been complicated by the fact that particles rarely distribute uniformly during processing. Clusters, particle-depleted zones, and quasi-cellular patterns emerge naturally, and the study set out to clarify how this heterogeneity governs deformation and failure.

Using two-dimensional mesoscale finite element models, the researchers built virtual composites that all contained the same global silicon carbide volume fraction but featured distinct cellular architectures. By systematically varying the local particle concentration within reinforcement-rich regions and the connectivity between those regions, they isolated the effects of heterogeneity on stress transfer, strain localization, crack initiation, and crack propagation. The approach allowed them to decouple two factors that are usually entangled in real materials: how much ceramic sits in a given neighborhood, and whether the ceramic-rich zones form a continuous network across the sample.

The simulations produced a striking result about strength. Moderate localization of silicon carbide particles actually improved tensile strength by increasing the efficiency of stress transfer from the ductile aluminum matrix to the stiff ceramic reinforcement. When particles concentrate moderately, load flows more directly into the hard phase, allowing the composite to carry more force before yielding. However, the benefit has a sharp limit. When localization becomes excessive and the particle-rich regions lose their connections to one another, the macroscopic load-bearing capability deteriorates. A fragmented architecture cannot distribute stress across the sample, and the composite fails at loads it would otherwise sustain.

Perhaps the most important finding is that damage initiation and crack propagation are controlled by different aspects of the topology. Local silicon carbide concentration primarily determines where and when damage begins, because mismatched deformation between particle-rich and particle-poor zones intensifies strain incompatibility. The stiffer particle-rich regions deform less than the surrounding matrix, generating localized stress concentrations that nucleate cracks. In contrast, the connectivity of the reinforcement network governs what happens after a crack forms, dictating whether the fracture races through the material or is deflected into a more tortuous, energy-absorbing path.

This division of labor has direct consequences for design. A continuous particle-rich framework promotes efficient load transfer across the entire sample, boosting strength, but it also provides a highway for cracks: once damage initiates, the fracture propagates rapidly along the connected particle-rich network. A disconnected network behaves in the opposite manner. It enhances crack deflection, forcing fractures to change direction and dissipate energy, which improves damage tolerance, but the lack of continuity reduces strengthening efficiency because load cannot flow as effectively into the ceramic phase.

The study establishes a topology-based design principle for heterogeneous silicon carbide-aluminum composites, emphasizing that reinforcement connectivity is essential for achieving a favorable balance between strength and damage tolerance. Rather than tuning only the global volume fraction, engineers should think about the architecture of the particle distribution as a separate design variable. The ideal composite would combine moderate particle localization for efficient stress transfer with enough network continuity to distribute load, while retaining sufficient architectural complexity to deflect cracks once they form.

The mesoscale finite element approach is significant because it bridges the gap between microscopic models of individual particles and macroscopic models of entire components. At the mesoscale, researchers can resolve the actual arrangement of reinforcement clusters and capture the cellular patterns that emerge during composite processing, while still simulating enough material to observe realistic crack paths. This scale is where heterogeneity matters most, and the new findings demonstrate that ignoring it can lead to serious mispredictions of composite performance.

For the broader materials community, the work reframes heterogeneity from a processing nuisance into a design opportunity. The same mechanisms that cause failure in poorly arranged composites can be exploited to create materials that are simultaneously strong and damage-tolerant. By controlling the local concentration and connectivity of reinforcement during manufacturing, whether through stir casting, powder metallurgy, or additive processing, it may be possible to engineer particle architectures that deliver the best of both regimes. The research suggests that the next generation of ceramic-metal composites will be designed not by adding more ceramic, but by arranging it more intelligently.

Subject of Research: Topology-mediated deformation and failure mechanisms in heterogeneous cellular SiCp/Al composites analyzed by mesoscale finite element simulation

Article Title: Topology-mediated deformation and failure mechanisms in heterogeneous cellular SiCp/Al composites revealed by mesoscale finite element analysis

Article References: Chen, H., Zheng, Z., Yuan, B., Ma, S., Wang, L., Gong, B., Ouyang, W., Chen, D., Liu, C., & Gao, X. (2026). Topology-mediated deformation and failure mechanisms in heterogeneous cellular SiCp/Al composites revealed by mesoscale finite element analysis. Frontiers in Materials, 13, Article 1961834. https://doi.org/10.3389/fmats.2026.1961834

Image Credits: AI Generated

DOI: 10.3389/fmats.2026.1961834

Keywords: metal matrix composites, silicon carbide, finite element analysis, crack propagation, topology, damage tolerance, 6061Al, heterogeneous microstructure, Topology-mediated, deformation, failure, mechanisms

The study focused on a real medical physics problem. Ultrasound scanners are the workhorses of modern hospitals—real-time, low-cost and free of ionising radiation—but they must be regularly quality-assured throughout their lifespan. Medical physicists perform this task by scanning test objects known as phantoms, which offer predictable and controlled imaging environments. The Edinburgh Pipe Phantom (EPP), a purpose-built device containing wall-less, fluid-filled pipes suspended in tissue-mimicking material, allows physicists to measure the resolution integral, a single dimensionless figure-of-merit representing the overall imaging performance of a greyscale ultrasound scanner. The conventional method requires an operator to manually identify the most superficial and deepest visible extent of each pipe—a time-consuming and potentially observer-dependent process that automation could dramatically accelerate.

The team trained a U-Net architecture with a ResNet-18 backbone, a convolutional pairing selected because it had achieved the best performance in the authors’ previous comparison of segmentation models. The network accepted single-channel greyscale ultrasound images and generated two-class logits for pipe and background, trained with cross-entropy loss with label smoothing and an Adam optimiser, with the ResNet-18 encoder initialised with weights pretrained on ImageNet. To facilitate uncertainty estimation, a two-dimensional dropout layer with a probability of 0.3 was applied independently to each encoder feature map prior to decoding, allowing the researchers to run 20 stochastic forward passes at inference time and measure pixel-wise variance across predictions—an approach known as Monte Carlo dropout, which can be interpreted as approximate Bayesian inference.

The dataset consisted of 162 images acquired from the Edinburgh Pipe Phantom using ten different ultrasound probes across three scanners: a GE Logiq E10, a Mindray A20 and a Samsung R20. A trained operator followed the conventional resolution integral measurement protocol, acquiring superficial and deep visibility measurements for each visible pipe as separate, independently optimised images. Half of the images were randomly selected and flipped horizontally to represent the two possible orientations in which an operator may hold the probe, and each image was cropped to a square region containing the target pipe and resized to 256 × 256 pixels. Ground truth binary masks were created by manually segmenting the pipes of interest using VIA annotation software, with the resolution integral values from manually segmented images differing from corresponding visual measurements by only 0.9 ± 0.3%—well within the previously reported 3% repeatability of resolution integral measurements.

Performance was assessed using stratified five-fold cross-validation, with the 162 images divided into five mutually exclusive outer folds stratified according to the individual ultrasound probe used for acquisition, so that the relative contribution of each of the ten probes was approximately balanced across the five folds. The model achieved an overall Dice score of 0.81 ± 0.03 and a 95th-percentile Hausdorff distance (HD95) of 11.98 ± 3.39 pixels, with held-out performance remaining broadly consistent across folds. A single forward pass required just 0.003 seconds on an NVIDIA GeForce RTX 4090 GPU workstation and 0.036 seconds on a CPU-only laptop, compared with approximately 30 seconds for a manual image measurement—an approximately 99.88% reduction in the segmentation component of the workflow.

But the raw accuracy numbers tell only part of the story. Seven segmentation errors were identified among the 162 held-out images: three complete failures in which no foreground mask was predicted at all, and four non-empty predictions in which the incorrect pipe was segmented. The complete failures occurred at a rate of 1.85%, and while they could be deterministically identified from the model output—simply by checking whether the predicted mask was empty—the subtler wrong-pipe errors proved far more challenging to catch prospectively.

To understand the model’s internal behaviour, the researchers deployed a battery of interpretability tools. Predictive entropy, derived from the SoftMax probabilities, was used as an approximation of data-related ambiguity, while Monte Carlo dropout variance served as an approximation of model-related, or epistemic, uncertainty. Input-gradient saliency maps were generated by backpropagating the gradient of the summed foreground-class score with respect to the input image, and Grad-CAM heatmaps were applied to the final residual block of each of the four encoder stages and to the last decoder block. Calibration was assessed using the Brier score—the mean squared difference between predicted foreground probability and observed binary label—and the expected calibration error (ECE), which compares average predicted probability with observed frequency across ten probability bins.

The results delivered a striking verdict on the relative value of these measures. The Dice score was strongly negatively associated with the Brier score (Spearman ρ = −0.96) and the ECE (ρ = −0.72), indicating that images with better segmentation overlap also tended to show closer agreement between predicted probabilities and reference labels. HD95 was positively associated with the Brier score (ρ = 0.82), so larger boundary errors tended to occur in images with larger probability errors. In contrast, predictive entropy and Monte Carlo dropout variance showed only weak associations with segmentation performance (|ρ| < 0.4), meaning neither uncertainty approximation functioned as a strong image-level correlate of segmentation quality. The mean Brier score was 0.17 ± 0.02 and the mean ECE was 0.18 ± 0.02. Mean Monte Carlo dropout variance was below 0.01 in every fold, indicating limited variation across stochastic passes under the selected dropout configuration—though the authors caution this should not be interpreted as proof that the model had negligible epistemic uncertainty.

The visual analyses provided complementary but necessarily limited information. In selected multi-pipe images, elevated entropy, variance or activation overlapped both target and non-target structures, including in complete failures. In the erroneous example, the model segmented the non-target pipe while elevated uncertainty and activation also overlapped parts of the intended target region. Earlier encoder maps retained finer spatial detail, whereas deeper encoder maps were coarser due to progressive downsampling, and the final decoder map reflected the reconstructed segmentation features. Across folds, attention localisation showed the strongest mean positive association with Dice score in the final decoder block (mean ρ = 0.60), followed by encoder stage 2 (mean ρ = 0.51), although fold-to-fold variability was substantial and no single layer provided a uniformly strong association in every fold. Crucially, the authors emphasise that these maps represent sensitivity or activation, not causal explanations of the decision process.

An exploratory image-level quality-control analysis then tested whether poor-quality outputs could be flagged automatically for review. Morphology-based indicators—bounding-box fill fraction, predicted area deviation and component count deviation—were evaluated alongside uncertainty-based mean entropy, with poor segmentation quality retrospectively defined as Dice < 0.50 and/or HD95 > 20 pixels among non-empty predictions. Component count and predicted area deviation methods both achieved a sensitivity of 1.00 by identifying all 23 poor-quality cases, while boundary box fill fraction and mean entropy identified 22. However, these indicators showed insufficient specificity to support their use as prospective quality-control criteria in the present dataset. Of the four wrong-pipe errors, only the component count deviation method identified all cases, and specificity was poor (< 0.1) in all methods except predicted area deviation, which achieved 0.58.

The authors are careful to frame their conclusions within the scope of what was actually tested. The cross-validation design balanced images from each probe across folds and therefore evaluated new images acquired within the known probe and scanner distribution; it did not test generalisation to an entirely unseen probe, scanner or phantom. The dataset was small and contained controlled phantom images rather than clinical ultrasound scans, lacking anatomical variability, pathology, patient motion and many acquisition artefacts. Only one architecture was evaluated, and external validation on a separate phantom or scanner was not performed. Reference masks were produced by one operator from measurements acquired by another, and while agreement in derived resolution integral values was high, independent boundary-level inter-rater reliability was not assessed.

For the intended medical-physics workflow, the researchers envision a future quality-control interface that displays the predicted pipe mask and flags outputs with an empty or implausible foreground region for manual review before the resolution integral is calculated. Probability calibration could be monitored retrospectively on labelled quality-assurance datasets, but it would not be available as an image-specific reference-free check in routine use. Uncertainty maps may help developers investigate recurring failure patterns, although presenting them directly to users would require evidence that they improve decisions rather than simply increasing cognitive burden. The framework should therefore be viewed as a development and audit tool for EPP automation, not as a validated clinical decision-support system.

The study’s broader message resonates far beyond the Edinburgh Pipe Phantom. As deep learning pushes further into computer-aided diagnostics to alleviate pressure on healthcare professionals, growing concern surrounds the trustworthiness of machine learning predictions and the clinical implications of errors—a concern exacerbated by the black-box problem, the inability to understand how a model reached its prediction. This research demonstrates that building genuinely trustworthy medical AI requires more than impressive accuracy metrics: it demands multimodal evaluation combining segmentation performance, calibration, uncertainty approximations and attention analyses, each interpreted within its proper limits. Calibration metrics, the study suggests, may deserve more attention than the uncertainty approximations that have dominated recent interpretability discussions. And simple deterministic checks—like verifying that a predicted mask is not empty—may catch the most catastrophic failures that sophisticated uncertainty methods miss. Before broader or deployable reliability claims can be made, however, independent validation, alternative architectures and uncertainty methods, and prospective threshold evaluation are all required. The path to trustworthy medical AI, this study shows, runs through honest accounting of what our evaluation tools can and cannot tell us.

Subject of Research: Beyond segmentation accuracy: understanding model reliability and failure modes in ultrasound image analysis

Article Title: Beyond segmentation accuracy: understanding model reliability and failure modes in ultrasound image analysis

Article References: Bricout, A., Hardman, D., Inglis, S., Pye, S., & Moran, C. M. (2026). Beyond segmentation accuracy: understanding model reliability and failure modes in ultrasound image analysis. Frontiers in Medical Technology, 8, Article 1918432. https://doi.org/10.3389/fmedt.2026.1918432

Image Credits: AI Generated

DOI: 10.3389/fmedt.2026.1918432

Keywords: Beyond, segmentation, accuracy, understanding, model, reliability, failure, modes, ultrasound, image, analysis, scientific research

The asymmetry in stability windows creates a natural division of labor that the review’s hybrid roadmap exploits. A halide electrolyte can sit against a cathode operating above 4.5 volts without the protective oxide coatings that sulfide systems demand, while a sulfide layer can provide the high-conductivity, mechanically compliant medium adjacent to the lithium anode. This bilayer architecture, in which each electrolyte is placed on the side of the cell where it is intrinsically more stable, sidesteps the weakest interface of each material class. The remaining challenge is the sulfide-halide junction itself, where interdiffusion, space charge effects, and possible formation of mixed-conducting interphases must be managed. Recent work suggests that brief annealing treatments or deliberately introduced interfacial dopants can suppress mutual diffusion while preserving low contact resistance, but the long-term evolution of such internal junctions under thousands of cycles remains an open question that operando studies are only beginning to address.

Critical current density, the current above which lithium filaments penetrate the electrolyte, serves as the most widely cited single metric for anode-side stability, yet its interpretation requires care because it is not an intrinsic material property. Measured values depend on stack pressure, temperature, electrolyte thickness, grain size, surface roughness, and the electrochemical history of the interface. The same argyrodite pellet can exhibit critical current densities varying by an order of magnitude depending on how it was densified and how well it wets the lithium electrode. This sensitivity is not a nuisance but a diagnostic opportunity: the dependence of critical current density on pressure and microstructure reveals which failure pathway dominates in a given system. A strong pressure dependence points to void-driven contact loss, whereas insensitivity to pressure combined with temperature dependence suggests electronic leakage through the electrolyte bulk or along grain boundaries as the rate-limiting step for filament nucleation.

Void formation during stripping deserves particular attention because it initiates a feedback loop that can destroy an otherwise stable cell. As lithium is extracted, the metal retreats from contact points, and if the local stripping rate exceeds the ability of lithium to creep and maintain contact, pores nucleate at the interface. These voids concentrate current on their rims, raising local current density by factors that scale with the void geometry. The elevated current accelerates stripping around the void perimeter, enlarging it, while the concentrated flux during the subsequent plating half-cycle preferentially deposits lithium into the void base, where it can bridge into the electrolyte as a filament. This chemo-mechanical coupling explains why stack pressure is such a powerful lever: modest pressures in the range of a few megapascals can suppress void nucleation entirely, but excessive pressure risks fracture of brittle electrolytes, particularly the halides, whose fracture toughness is generally lower than that of dense sulfide ceramics.

Grain boundaries have emerged as double-edged features in this failure landscape. In sulfide electrolytes, grain boundaries can be either faster or slower ion conduction pathways than the grain interiors depending on composition and dopant segregation, and their electronic character varies similarly. When grain boundaries carry appreciable electronic conductivity, whether intrinsic or induced by partial decomposition, they become preferential highways for lithium nucleation inside the ceramic, producing the characteristic trans-granular and inter-granular filament patterns observed in post-mortem cross-sections. In halides, the picture is complicated by the tendency of some compositions to form electronically conductive reduced phases at low potentials, meaning that the anode-side interface of a halide must be protected even when the bulk electrolyte is an excellent ionic conductor. This is why bilayer designs typically interpose a thin sulfide or lithium-compatible interlayer between lithium metal and the halide layer rather than exposing the halide directly.

Space charge layers, arising from the mismatch in lithium chemical potential between the metal and the electrolyte, redistribute mobile ions and vacancies over nanometer distances at the contact. Although the affected region is thin, its consequences are disproportionate: lithium ion flux can be locally concentrated or depleted, interfacial resistance can rise substantially, and the altered defect population can change the local electronic conductivity. In sulfide systems, the space charge layer at the lithium contact often manifests as a lithium-rich, electronically leaky region that seeds inhomogeneous plating. Mitigation through ultrathin artificial interphases, such as lithium fluoride or lithium nitride layers deposited by evaporation or formed in situ by controlled reaction, works partly by flattening the chemical potential gradient and partly by providing a phase whose decomposition products are themselves ionically conductive and electronically insulating. The design rule that emerges is that an ideal interphase must be simultaneously ion-conducting, electron-blocking, mechanically soft enough to accommodate volume changes, and thermodynamically stable against both lithium and the electrolyte.

The role of electronic leakage deserves emphasis because it reframes the traditional figure of merit for electrolytes. A material can possess outstanding ionic conductivity and still fail catastrophically if its electronic conductivity, even at the level of parts per billion relative to its ionic transport, allows parasitic lithium deposition within the bulk. Over long times, the product of electronic conductivity and operating time determines the extent of internal plating, which is why cells that perform well in short-term tests can still short after hundreds of hours of float or cycling. This time-dependent degradation mode favors compositions and dopants that widen the electronic band gap or introduce electron traps, and it explains the observed benefit of certain aliovalent substitutions that pin the Fermi level away from the conduction band edge. Screening electrolytes by electronic conductivity, not merely ionic conductivity, is therefore becoming standard practice in the field.

Manufacturability considerations increasingly shape which laboratory strategies can survive translation. Sulfides offer the advantage of cold-press densification and room-temperature processability, but their moisture sensitivity demands dry-room handling at industrial scale, since hydrogen sulfide evolution upon air exposure poses both safety and material-loss problems. Halides are generally more tolerant of ambient handling, though many still require controlled atmospheres, and their synthesis often involves expensive indium or yttrium precursors that pressure cost targets. Coating strategies that work in the laboratory, such as atomic layer deposition of conformal alumina or lithium niobate layers, face throughput constraints when scaled to the areas required for automotive cells, motivating research into solution-based and roll-to-roll coating alternatives. The review’s staged roadmap, moving from simple protective coatings toward AI-guided, application-specific interface designs by the mid-2030s, reflects the reality that no single interfacial solution will satisfy both high-energy-density EV packs and lower-cost stationary storage simultaneously.

Operando diagnostics are transforming the field’s ability to distinguish among competing failure hypotheses. Synchrotron X-ray computed tomography now resolves filament growth in three dimensions in real time, revealing that penetration often initiates far from the geometric center of current distribution, at defects invisible to surface characterization. Neutron depth profiling quantifies lithium distribution through the electrolyte thickness, directly imaging internal plating. Electrochemical impedance spectroscopy, when interpreted with appropriate equivalent circuits and combined with distribution of relaxation times analysis, can separate interfacial resistance growth from bulk degradation. Coupling these measurements with acoustic emission and dilatometry links mechanical events, such as cracking or delamination, to specific points in the charge-discharge cycle. The convergence of evidence from these techniques supports the review’s central claim that interface failure is inherently multifactorial, and it provides the empirical basis for the coupled chemical-electrochemical-mechanical framework that organizes the comparative analysis.

Looking forward, the most promising research directions combine the complementary strengths of the two material classes rather than seeking a single universal electrolyte. Composite designs that embed halide phases within a sulfide matrix, or vice versa, aim to harvest halide oxidative stability and sulfide reductive stability in one continuous medium, though percolation, phase compatibility, and interfacial ion transport between the constituent phases must be engineered deliberately. Doping strategies that simultaneously suppress electronic leakage and enhance grain boundary ionic transport offer another path, particularly for sulfides where rare-earth and halogen substitutions have shown synergistic effects. On the mechanical side, designing electrolytes with controlled porosity or introducing compliant secondary phases may allow cells to tolerate volume changes without the high stack pressures that complicate pack-level engineering. Ultimately, the practical success of lithium-metal solid-state batteries will rest not on any single breakthrough but on the disciplined, material-class-specific integration of chemical, electrochemical, and mechanical interface engineering, validated under the realistic pressures, currents, and lifetimes that commercial deployment demands.

Subject of Research: Interface failure mechanisms and engineering strategies in sulfide and halide solid electrolytes for lithium metal solid-state batteries

Article Title: Interface failure mechanisms and engineering strategies in sulfide and halide solid electrolytes for lithium metal solid-state batteries

Article References: Tron, A. (2026). Interface failure mechanisms and engineering strategies in sulfide and halide solid electrolytes for lithium metal solid-state batteries. Frontiers in Batteries and Electrochemistry, 5, Article 1844424. https://doi.org/10.3389/fbael.2026.1844424

Image Credits: AI Generated

DOI: 10.3389/fbael.2026.1844424

Keywords: Interface, failure, mechanisms, engineering, strategies, sulfide, halide, solid, electrolytes, lithium, metal, solid-state

The choice of the area under the precision-recall curve as a complementary metric also reflects the realities of critical care prediction. With an event prevalence near 13 percent, an AUROC of 0.804 can look impressive while concealing weak performance in the region clinicians care about most: the high-risk tail. The AUPRC of 0.296 in eICU-CRD provides a more sobering and more informative picture, since the theoretical ceiling for that metric is 1.0 and the no-skill baseline equals the prevalence itself. The gap between 0.296 and the prevalence of roughly 0.134 indicates real but modest enrichment of true positives among flagged patients. This is consistent with the post hoc operating analysis targeting approximately 85 percent specificity, where the positive predictive value reached 0.406, meaning that roughly four in ten patients flagged as high risk actually died, while the negative predictive value of 0.942 indicates that a low-risk designation was considerably more reliable. This asymmetry is not a flaw unique to this model; it is a mathematical consequence of predicting an uncommon event, and it shapes how any such tool could reasonably be deployed, most plausibly as a rule-out or prioritization aid rather than a definitive rule-in test.

The patient-paired comparison against XGBoost is methodologically noteworthy because it evaluates discrimination differences within the same patients rather than across independent samples. This paired design reduces the variance of the estimated difference and increases statistical power, which is why a difference of 0.027 to 0.032 in AUROC could be reported with confidence intervals excluding zero. In absolute terms, such differences are modest, and their clinical significance remains an open question; however, the consistency of the advantage across both internal and external cohorts, and the additional finding that a matched FT-Transformer-style baseline without the clinical modifications reached only 0.781 externally, suggests that the domain-specific additions carried measurable weight beyond generic attention-based tabular modeling. The ablation analysis reinforces this interpretation: removing feature-token encoding produced the largest single degradation in external AUROC, a loss of 0.031, indicating that preserving the identity of each variable as a distinct learnable unit, rather than collapsing all inputs into a flat vector, was the component most responsible for the model’s transportability.

The explicit representation of missingness deserves elaboration because it runs counter to common preprocessing practice. Many machine-learning pipelines impute missing values or discard variables with high missingness rates, but in intensive care the pattern of what was measured is itself informative. Ordering an arterial blood gas, a brain natriuretic peptide, or repeated lactate measurements reflects clinical concern and resource intensity, and the absence of a measurement can signal either stability or simply that the test was never indicated. By encoding missingness as an explicit component of each token alongside the value, variable identity, and clinical group, the architecture allows the model to learn these contextual signals rather than erasing them. This design choice aligns with a growing body of literature recognizing informative missingness as a signal rather than noise in EHR data, though it also introduces a vulnerability: if documentation practices differ across institutions, the meaning attached to a missing value may shift, and this could partly explain the drop in AUROC from 0.849 internally to 0.804 externally.

The 24-hour landmark design itself carries both strengths and constraints worth understanding. By fixing the prediction time at 24 hours after ICU admission, the model avoids the ambiguity of predicting at variable time points and ensures that every patient has a comparable observation window, which simplifies both development and interpretation. However, this design necessarily excludes information from the first hours that might be decisive, and it means the model’s output arrives after a full day of intensive observation has already elapsed. The authors appropriately note that admission-time applicability has not been demonstrated, and this caveat is substantive rather than formulaic: a model that requires 24 hours of accumulated data cannot inform the earliest resuscitation decisions, though it may still be valuable for subsequent daily reassessment, escalation conversations, and goals-of-care planning, where the trajectory of the first day is highly prognostic.

The choice of in-hospital all-cause mortality as the endpoint also shapes interpretation. This endpoint is reliably captured in both source databases and is unambiguous, but it is influenced by discharge practices, palliative care pathways, and limits-of-treatment decisions that vary across institutions and over time. Two patients with identical physiology may have different recorded outcomes depending on whether death occurred before or after discharge, and time-limited trials of intensive therapy are increasingly common in heart failure care. Models trained on such endpoints may partially learn institutional or temporal patterns in end-of-life decision-making rather than pure physiology. The span of MIMIC-IV, covering admissions from 2008 to 2019, means the training data include eras with different documentation systems and care standards, while eICU-CRD covers only 2014 to 2015, a narrower and potentially different practice window. These temporal and geographic mismatches are inherent to retrospective database research and are part of why the observed external performance decrement, though modest, is expected rather than surprising.

It is also worth situating the cohort sizes in context. With 11,156 intensive care stays and 1,484 deaths in the development database and 9,837 stays and 1,319 deaths in the external database, the study is among the larger heart failure-specific critical care prediction efforts, which matters because transformer architectures with many parameters are prone to overfitting on small cohorts. The partitioning of the development data into training, validation, and internal test sets of roughly 7,809, 1,673, and 1,674 patients follows standard practice, with the internal test set held out from all model selection decisions. Still, because MIMIC-IV derives from a single institution, the internal test set shares that institution’s population and documentation culture with the training data, so the external result in eICU-CRD is the more meaningful estimate of real-world transportability, and the roughly 0.045 AUROC decrement between the two settings offers a realistic gauge of performance loss under distribution shift.

The inclusion of nurse-charted monitoring data, intake and output records, and organ support variables in the feature set reflects an important aspect of critical care informatics that is often overlooked in models built solely on laboratory values and demographics. Fluid balance trajectories, urine output trends, and the intensity of nursing observation carry prognostic information in decompensated heart failure that static snapshots miss. The clinical-group embedding approach, which tags each token with its physiological or procedural domain, allows the attention mechanism to learn interactions within and across domains, such as the joint pattern of rising creatinine, falling urine output, and new vasopressor exposure that the authors cite as clinically meaningful context. Whether such learned interactions translate into explanations that clinicians find trustworthy remains an open question; architectural traceability, in which one can inspect attention weights or token contributions, is not equivalent to validated interpretability, and the authors are careful not to conflate the two.

Finally, the path from these results to bedside deployment runs through several gates that retrospective validation cannot clear. Prospective evaluation would need to establish that the model performs acceptably on live data streams with real-time missingness, that its predictions arrive early enough in the admission to be actionable, that integration into clinical workflows changes decisions or outcomes rather than merely producing numbers, and that performance holds across the broader diversity of hospitals, electronic health record systems, and patient populations beyond those represented in the two source databases. Regulatory considerations, local calibration updates, and monitoring for performance drift over time would all be required. The authors’ framing that the findings support prospective investigation but do not yet demonstrate clinical utility is an accurate and appropriately conservative summary of where this work stands within the broader translation pipeline for clinical prediction models.

Subject of Research: Feature-token clinical transformer for 24-h landmark mortality risk stratification in critically ill patients with heart failure: development and multicenter external validation

Article Title: Feature-token clinical transformer for 24-h landmark mortality risk stratification in critically ill patients with heart failure: development and multicenter external validation

Article References: Li, M., Zhou, Y., & Li, C. (2026). Feature-token clinical transformer for 24-h landmark mortality risk stratification in critically ill patients with heart failure: development and multicenter external validation. Frontiers in Cardiovascular Medicine, 13, Article 1945947. https://doi.org/10.3389/fcvm.2026.1945947

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1945947

Keywords: Feature-token, clinical, transformer, landmark, mortality, risk, stratification, critically, patients, heart, failure, development

The study drew on the Zigong Heart Failure Database, a collection of electronic medical records from 2,008 patients hospitalized with heart failure at Zigong Fourth People’s Hospital between December 2016 and June 2019. After excluding patients with missing laboratory values or incomplete readmission data, the researchers assembled a final cohort of 1,854 patients, most of them elderly, with 73.4 percent aged over 70 years. The team then divided the patients into four groups based on their RAR values and tracked whether they were readmitted to the hospital for any reason within six months of their index admission.

The results were striking. Overall, 38.5 percent of the patients, 714 of the 1,854, were readmitted within six months. But the risk was not evenly distributed. In unadjusted analyses, every one-unit increase in RAR was associated with a 57 percent higher risk of readmission, with a hazard ratio of 1.57 and a 95 percent confidence interval spanning 1.27 to 1.93. Even after the researchers adjusted for a long list of potential confounders, including age, sex, body mass index, cardiac function class, troponin and BNP levels, C-reactive protein, comorbidity burden, and the full range of heart failure medications, the association held firm, with a hazard ratio of 1.52.

When the researchers compared the highest RAR quartile with the lowest, the difference remained clear. Patients in the top quartile faced a 39 percent greater risk of six-month readmission than those in the bottom quartile, with a hazard ratio of 1.39 and a confidence interval of 1.10 to 1.76. Kaplan-Meier curves, which track cumulative readmission rates over time, showed that the high-RAR group diverged visibly from the low-RAR group, and a log-rank test confirmed the difference was statistically significant at P = 0.0025.

What makes RAR so informative is the biology behind its two components. Red cell distribution width, or RDW, measures the variability in the size of circulating red blood cells, a value routinely reported on every complete blood count. In recent years, RDW has emerged as a surprisingly powerful marker of chronic low-grade inflammation, and elevated RDW has been linked to more severe inflammation and to disorders of iron mobilization, in which iron is locked away in inflammatory stores rather than being available for red blood cell production. This iron sequestration can inhibit the maturation of red cells driven by erythropoietin, producing the anemia of chronic disease, a common companion of advanced heart failure.

Albumin, the second component, is the most abundant protein in human serum and a workhorse of physiology, with anti-inflammatory, antioxidant, anticoagulant, and antiplatelet properties. Serum albumin concentration is a well-established indicator of both nutritional status and inflammatory response, and low albumin levels in cardiovascular disease reflect the combined toll of chronic inflammation, malnutrition, and vascular leakage. By dividing RDW by albumin, RAR captures two dimensions of physiological dysfunction at once: the inflammatory and hematologic stress reflected in the numerator, and the nutritional and anti-inflammatory reserve reflected in the denominator. The researchers argue that this composite signal may carry more predictive weight than either measurement alone.

The association proved remarkably robust across the population. Subgroup analyses stratified by sex, age below or above 70 years, body mass index, New York Heart Association functional class, and the use of medications including diuretics, beta-blockers, ACE inhibitors or ARBs, statins, and inotropic agents all showed consistent results, with no statistically significant interactions. In other words, the link between RAR and readmission was not driven by any particular patient profile or treatment pattern, strengthening the case that RAR functions as an independent predictor.

The findings fit into a growing body of evidence on RAR as a prognostic marker. Previous studies have linked elevated RAR to mortality in patients with heart failure, acute myocardial infarction, atrial fibrillation, diabetes mellitus, and chronic kidney disease. Earlier work also found that higher RDW alone predicted three-month readmission in heart failure patients, while a related marker, the red cell distribution width-to-platelet ratio, showed no significant association with six-month readmission. The new study extends this literature by combining the two biomarkers into a single ratio, incorporating a broader set of confounders, and focusing on an East Asian population, a group that had been underrepresented in prior research.

The clinical appeal of RAR lies in its accessibility. Both RDW and albumin are measured on routine blood draws, costing essentially nothing beyond tests already performed on nearly every hospitalized patient. If validated in prospective studies, RAR could be calculated at the bedside within hours of admission, flagging patients who need closer follow-up, more aggressive medication optimization, or earlier post-discharge contact. With roughly one million heart failure admissions and readmissions occurring annually in the United States alone, and between 20 and 50 percent of discharged patients returning within a year, even modest improvements in risk stratification could translate into substantial savings and better outcomes.

The authors are careful to note the limits of their work. As a retrospective cohort study, the findings demonstrate correlation rather than causation. RAR was measured only once, at admission, so the study cannot capture how the ratio changes over time. Residual confounding cannot be excluded despite extensive statistical adjustment, and the database lacked detailed reasons for readmission, meaning the outcome reflects all-cause rehospitalization rather than heart failure-specific events. Still, the researchers conclude that RAR may serve as a simple, cost-effective predictor of readmission during the post-discharge vulnerability period, and they plan to investigate whether the marker is associated with the development of heart failure in broader populations. For now, the study adds a compelling entry to the search for cheap, reliable signals hidden in the most ordinary of laboratory tests.

Subject of Research: Association of the red cell distribution width/albumin ratio with 6-month readmission risk in heart failure patients

Article Title: Association of the red cell distribution width/albumin ratio with 6-month readmission risk in heart failure patients

Article References: Wang, H., Yang, L., Liu, Z., Wang, Y., Lv, X., Ma, R., & Li, M. (2026). Association of the red cell distribution width/albumin ratio with 6-month readmission risk in heart failure patients. Frontiers in Cardiovascular Medicine, 13, Article 1842863. https://doi.org/10.3389/fcvm.2026.1842863

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1842863

Keywords: Association, cell, distribution, width, albumin, ratio, month, readmission, risk, heart, failure, patients